Trade name of the drug: Bakido Active ingredients (INN): ofloxacin, ornidazole Dosage form: infusion solution Composition: 100 ml of the solution contains: active ingredients: ofloxacin - 200.0 mg; ornidazole - 500.0 mg; excipients: sodium chloride, Trilon B, sodium hydroxide, hydrochloric acid, water for injection. Description: transparent solution of light yellow color. Pharmacotherapeutic group: Antibacterial synthetic agent. ATX Code: J01RA09
Pharmacological properties Bakido is a combined drug, Ofloxacin is an antimicrobial agent of the fluoroquinolone group with a wide spectrum of action. The bactericidal effect of ofloxacin, like other fluoroquinolones, is due to its ability to block the bacterial enzyme DNA gyrase. Ofloxacin has a wide spectrum of action: it is active against most Gram-negative bacteria - Escherichia coli, Klebsiella, Proteus, Salmonella, Yersinia, Providencia, Shigella, Enterobacter, Citrobacter, Providentia, Pseudomonas, Hafnia, as well as Staphylococcus (including microflora resistant to methicillin and other antibiotics). Neisseria, Mycoplasma, Chlamydia, Campylobacter, Brucella, Vibrio, Aeromonas, Plesiomonas, Haemophilus influenzae, Versinia are also sensitive to the drug. Non-constant sensitivity to the drug are: enterococci, streptococci (S.pyogenes, S.pneumoniae, S.viridans), Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter, Mycoplasma (M.hominis, M.pneumoniae), Mycobacterium tuberculosis, as well as Mycobacterium fortuitum, Gardnerella vaginalis, Ureaplasma , Bruccella. Anaerobic bacteria (except B. urealiticus), Treponema pallidum, viruses, fungi and protozoa are insensitive to the drug. Ornidazole is an antiprotozoal and antibacterial agent. It is active against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, as well as some anaerobic bacteria, such as: Bacteroides, Clostridium spp., Fusobacterium spp. and anaerobic cocci. According to the mechanism of action, ornidazole is a DNA-tropic drug with selective activity against microorganisms having enzyme systems capable of restoring the nitro group and catalyzing the interaction of ferridoxin group proteins with nitro compounds. After the penetration of the drug into the microbial cell, the mechanism of its action is due to the restoration of the nitro group under the influence of the nitroreductases of the microorganism and the activity of the already reduced nitroimidazole. The recovery products form complexes with DNA, causing its degradation, disrupt the processes of DNA replication and transcription. In addition, the metabolic products of the drug have cytotoxic properties and disrupt the processes of cellular respiration.
Pharmacokinetics Ofloxacin is rapidly and almost completely adsorbed. The bioavailability of the drug reaches almost 100%. The maximum concentration of ofloxacin in the blood plasma is determined after 0.5 1 hour. The half-life is 5-7 hours. About 90% of the drug is excreted unchanged by the kidneys, and about 5% of the administered Ornidazole is metabolized and distributed in many tissues and biological fluids of the amount. The body, such as bile, saliva, pleural, peritoneal and cerebrospinal fluids (approximately 43% of the concentration in blood plasma), vaginal secretions, bone tissue, liver, red blood cells. Binding to plasma proteins is less than 20%. Ornidazole penetrates the placental barrier, is released into breast milk. Almost 30-60% of the drug is metabolized in the body by hydroxylation, oxidation and glycosylation. The main metabolite (2-oxymetronidazole) it also has an antiprotozoal and antibacterial effect. Ornidazole is excreted mainly in the urine (60-80%), partially with bile unchanged in the form of metabolites for 5 days after a single injection.
Indications for use Treatment of mixed infections caused by pathogens sensitive to the drug (microorganisms and protozoa): - diseases of the genitourinary system: acute and chronic pyelonephritis. prostatitis, cystitis, epididymitis, complicated or recurrent urinary tract infections; - sexually transmitted diseases caused by penicillin-resistant gonococci, chlamydia, trichomonas and other microorganisms; - acute, chronic and recurrent respiratory tract infections (bronchitis, pneumonia) caused by Haemophilus influenzae or other gram-negative pathogens, as well as Staphylococcus aureus, E. coli, Klebsiella, Enterobacteria, proteus, Pseudomonas, Legionella, Staphylococcus; - infections of the abdominal cavity and biliary tract, as well as amsbidenamoebic dysentery, extra-intestinal forms, especially amoebic abscess of the liver; giardiasis, typhoid fever, salmonellosis, shigellosis; - chronic and recurrent infections of the ear, throat and nose, if they are caused by gram-negative pathogens (including Pseudomonas) or Staphylococcus, - oral infections, acute necrotic ulcerative gingivitis, - infections of soft tissues and skin; - infections of bones and joints; - prevention of infectious complications in patients with immunodeficiency or neutropenia; - preoperative prevention or postoperative treatment of surgical infections, especially in gastroenterology. - gynecological diseases.
Method of administration and dosage The dose of the drug depends on the severity and type of infection. For an adult, it ranges from 100 ml to 400 ml per day. It is allowed to prescribe up to 200 ml of the drug as a daily single dose (for morning use). Recommended doses: Respiratory tract infections, as well as throat, ear and nose - 200 ml per day (in severe cases up to 300-400 ml per day) Infections of the skin and soft tissues - 200 ml per day Infections of bones and joints - 200 ml per day Abdominal infections - 200 ml per day Bacterial enteritis - 200 ml per day Infections of the upper urinary tract and genitals - 200 ml per day Uncomplicated lower urinary tract infections - 100 ml per day
Side effects From the gastrointestinal tract: metallic taste and dry mouth, nausea, heaviness and abdominal pain, loss of appetite, diarrhea, vomiting; From the central nervous system: drowsiness, headache, dizziness, tremor, rigidity, impaired coordination of movements, temporary loss of consciousness, fatigue, ataxia, convulsions, confusion, signs of sensory or mixed peripheral neuropathy; From the hematopoietic system: very rarely there is a decrease in the number of leukocytes, erythrocytes and/or blood plates (leukopenia, agranulocytosis, anemia, thrombocytopenia, pancytopenia); From the cardiovascular system: hypotension, tachycardia; Other: increased creatinine levels in the blood, increased activity of liver enzymes, bilirubin, arthralgia, myalgia; Allergic reactions: skin rash, itching, photosensitization, Quincke's edema, erythema multiforme; Other side effects: hypoglycemia in diabetic patients who take hypoglycemic drugs.Contraindications Further repeatability to the preparation or ego component; apostillepilepsia; damaged central nervous system. Do not follow the appointment of detergent child, subrostcam, beremenn urgem women and driving material, postcontact notdecognabdachdannabh relative safety in the changed Bakido DLA Apostille groupp patient.
Pharmacovigilance interactions In the event of a temporary change with antacid extravasation or soderatime iron remedies, the function of the Bakido is reduced, in swazz with Cem preparation is reduced for 2 hours to or cherez 2 hours after taking specified wawrabh remedy. In the case of non-steroidal use of antiviral drugs, antiviral agents (VFP) have increased the risk of developing sudorog., Probenecid, cimetidine, furosemide, and methotrexate harass in aposemide and can further expose toxicity. Increases glibenclamide concentration. Do not follow up with cheetah (risk of precipitations). Bakido enhanceringforexfect anticoagulant coumarinic repellent, prolongiruyuronium bromide relaxing action vecuronium bromide.
Specificservice instructions During the treatment of Bakido, it is necessary to avoid direct sunlight, exposure to ultraviolet rays (mercury-quartz lamps, solarium) due to the high risk of photosensitization. Bakido does not appear to be a preparation for treatment of pneumonia ambulatory ambulatory pneumoniae (inflammatory pneumonia in major cases of pneumococcus). In the case of the developments in the case of povtn, extravehicular fecundation, especially co storon, nervous system, allergenic reaction, preparation necessary to cancel, Development of diarei during treatment Bakido can be B. B. symptomatom pseudomembranous colitis. In case of suspected development, the complex intake of Bakido should not be discontinued and urgent antibacterial therapy (vnutri — vancomycin or metronidazole) should be appointed. Detergent evaluative peristaltic quiche, contraindicated Apostille! Diseasehave malfunctionm or thatjapeddevelopmentnotelyexpress (shirroz) do not followingexpress the average dose of the preparation (200 ml). In case of ingestion of Bakido, secondary infections may develop (in patients with Rostom-resistant pancreas). In case of secondary infections in time treatments are developed, the appropriate measure is available. The preparation is not compatible with alkogolem! Replacement for beremenations and lactation Detergent do not follow the appointment of beremenn Urgam and steering female. Influence of the capacity of the chieftain of the Motor Transport and management mechanisms Some side effects of the drug (dizziness, drowsiness, confusion, impaired vision and hearing, impaired coordination of movements) may reduce the speed of psychomotor reactions and impair the ability to drive vehicles or work with potentially dangerous mechanisms.
Peredosis Symptoms: from the central nervous system: dizziness, confusion; convulsions; from the digestive system: nausea and vomiting, erosion of mucous membranes. Treatment: symptomatic. Specific antidote no.
Shape in aposematic In polymerna urgane vial around P > low tops of 100 ml 1 vial packed in cardboard box instead of with medical instructions,
Feeding conditions Eat in dry and protected from the world, at a temperature of up to 25. Eat in an uncomplicated place.
Shelf life 2 years. Do not follow the giant then and there the length of the year.
Terms of leave from pharmacy Recipe.
Manufacturer JEDUX PARENTERALS PVT.LTD.
Owner registration certificates HARASHA PHARMA PVT. LTD., India
Name and address organizations making claims (proposals) for quality medicinal products of territories Republic of Uzbekistan «FUTURE-WORLD GROUP» Republic of Uzbekistan, Tashkent, Chilanzarsky r-n, str. Sanyat 13A. Tel.:+99891 134 94 14 E-mail: info.fwg@yandex.com
